journal article·2025-04Open access

An aggregation-induced emission-active lysosome hijacker: Sabotaging lysosomes to boost photodynamic therapy efficacy and conquer tumor therapeutic resistance

Hang Zou, Pingping Wang, Zhihao Bai, Liping Liu, Jingtong Wang, Yanfang Cheng, Bairong He, Zujin Zhao, Lei Zheng

Abstract

Therapeutic resistance is a major challenge in clinical cancer theranostics, often leading to treatment failure and increased patient mortality. Breaking this therapeutic deadlock, enhancing the efficacy of clinical treatments, and ultimately improving patient survival rates are both highly desirable and significantly challenging goals. Herein, we have developed a new fluorescent luminogen, QM-DMAC, which features aggregation-induced emission (AIE), and exceptional viscosity-responsive properties. The AIE-active QM-DMAC can specifically stain lysosomes in tumor cells, offering a high signal-to-noise ratio and enabling specific visualization of variations in lysosomal viscosity, such as those induced by inflammation or autophagy. Furthermore, QM-DMAC effectively generates reactive oxygen species (ROS) under white light irradiation, which precisely induces ROS-mediated lysosomal membrane permeabilization (LMP) and lysosome rupture. This ultimately causes severe cell damage and restores the sensitivity of tumor cells to radiotherapy and chemotherapy. Thus, QM-DMAC serves as a highly efficient lysosome-targeting photosensitizer and an excellent therapeutic sensitizer. This innovative “lysosome hijacking” strategy significantly maximizes the efficacy of photodynamic therapy, conquering therapeutic resistance and boosting the synergistic therapeutic effect when integrated with conventional radiotherapy or chemotherapy. It provides a novel approach to the design of theranostic agents for clinical cancer theranostics. An AIE-active lysosome-targeting therapeutic sensitizer has been developed. With satisfactory ROS generation capability, it can dramatically induce ROS-mediated lysosomal membrane permeabilization and specifically ablates tumors via photodynamic therapy. Furthermore, it restores the sensitivity of tumor cells to radiotherapy and chemotherapy, thereby overcoming therapeutic resistance, acting as an excellent therapeutic sensitizer and exhibiting extraordinarily impressive antitumor efficiency.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Luminescence and Fluorescent Materials · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (54)

Show source-provided references
1. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives10.1038/s41392-024-01885-2 ↗
2. Facing inevitable PARPis resistance: mechanisms and therapeutic strategies for breast cancer treatment
3. Drug-tolerant persister cells in cancer: the cutting edges and future directions10.1038/s41571-023-00815-5 ↗
4. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance10.1038/s41568-021-00427-0 ↗
5. Intratumor heterogeneity: the Rosetta stone of therapy resistance10.1016/j.ccell.2020.03.007 ↗
6. Enhancing X-ray sensitization with multifunctional nanoparticles10.1002/smll.202400954 ↗
7. Biomarker-induced gold aggregates enable activatable near-infrared-II photoacoustic image-guided radiosensitization
8. Phytochemicals in cancer cell chemosensitization: current knowledge and future perspectives10.1016/j.semcancer.2020.06.014 ↗
9. NIR activated multimodal therapeutics based on metal-phenolic networks-functionalized nanoplatform for combating against multidrug resistance and metastasis10.1002/smll.202206174 ↗
10. Good radiosensitizer hunting10.1200/JCO.22.02350 ↗
11. Lysosomes as dynamic regulators of cell and organismal homeostasis10.1038/s41580-019-0185-4 ↗
12. Endocytosis in cancer and cancer therapy10.1038/s41568-023-00574-6 ↗
13. The biology, function, and applications of exosomes in cancer10.1016/j.apsb.2021.01.001 ↗
14. The role of endolysosomal trafficking in anticancer drug resistance10.1016/j.drup.2021.100769 ↗
15. Lysosomes as mediators of drug resistance in cancer10.1016/j.drup.2015.11.004 ↗
16. The endo-lysosomal damage response10.1146/annurev-biochem-030222-102505 ↗
17. Targeting lysosomal quality control as a therapeutic strategy against aging and diseases10.1002/med.22047 ↗
18. Control of lysosomal-mediated cell death by the pH-dependent calcium channel RECS110.1126/sciadv.abe5469 ↗
19. Carbon black nanoparticles induce cell necrosis through lysosomal membrane permeabilization and cause subsequent inflammatory response10.7150/thno.34065 ↗
20. Boron nitride nanosheets can induce water channels across lipid bilayers leading to lysosomal permeabilization10.1002/adma.202103137 ↗
21. Intra-lysosomal peptide assembly for the high selectivity index against cancer10.1021/jacs.3c04467 ↗
22. Targeting lysosomes in human disease: from basic research to clinical applications10.1038/s41392-021-00778-y ↗
23. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy10.1021/acs.chemrev.1c00381 ↗
24. Tuning organelle specificity and photodynamic therapy efficiency by molecular function design10.1021/acsnano.9b04430 ↗
25. Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment10.1016/j.addr.2022.114344 ↗
26. Ultrasound-enhanced chemo-photodynamic combination therapy by using albumin "Nanoglue"-Based nanotheranostics10.1021/acsnano.9b09827 ↗
27. Programming DNA nanoassembly for enhanced photodynamic therapy10.1002/anie.201912574 ↗
28. Mitochondrion, lysosome, and endoplasmic reticulum: which is the best target for phototherapy?10.1016/j.jconrel.2022.09.037 ↗
29. State-of-the-art self-luminescence: a win-win situation10.1039/D2CS00228K ↗
30. Aggregation-induced emission photosensitizer-engineered anticancer nanomedicine for synergistic chemo/chemodynamic/photodynamic therapy10.1002/adhm.202303643 ↗
31. Theranostic applications of biomolecule-responsive aggregation-induced emission luminogens
32. Aggregation-induced emission: recent advances in materials and biomedical applications10.1002/anie.202000845 ↗
33. Targeted antibacterial photodynamic therapy with aggregation-induced emission photosensitizers10.1002/INMD.20230038 ↗
34. A bright two-photon lipid droplets probe with viscosity-enhanced solvatochromic emission for visualizing lipid metabolic disorders in Deep tissues10.1002/adfm.202303627 ↗
35. Exploring and leveraging aggregation effects on reactive oxygen species generation in photodynamic therapy10.1002/agt2.540 ↗
36. Lipid droplet-targeted NIR AIE photosensitizer evoking concurrent ferroptosis and apoptosis10.1002/agt2.516 ↗
37. An AIE photosensitizer with simultaneous type I and type II ROS generation: efficient bacterial elimination and hypoxic tumor ablation10.1002/adfm.202301692 ↗
38. High-performance quinoline-malononitrile core as a building block for the diversity-oriented synthesis of AIEgens10.1002/anie.201913249 ↗
39. Robust sky-blue aggregation-induced delayed fluorescence materials for high-performance top-emitting OLEDs and single emissive layer white OLEDs10.1016/j.cej.2022.138919 ↗
40. Tuning the singlet-triplet energy gap: a unique approach to efficient photosensitizers with aggregation-induced emission (AIE) characteristics10.1039/C5SC01733E ↗
41. Aggregation-induced emission: the whole is more brilliant than the parts10.1002/adma.201401356 ↗
42. Aggregation-induced emission: phenomenon, mechanism and applications10.1039/b904665h ↗
43. Type I photosensitizers based on phosphindole oxide for photodynamic therapy: apoptosis and autophagy induced by endoplasmic reticulum stress10.1039/D0SC00785D ↗
44. De novo design of type-l photosensitizer agents based on structure-inherent low triplet energy for hypoxia photodynamic therapy10.1039/D4MH01167H ↗
45. Small molecule based fluorescent chemosensors for imaging the microenvironment within specific cellular regions10.1039/D1CS00645B ↗
46. Rational design of orange-red emissive carbon dots for tracing lysosomal viscosity dynamics in living cells and zebrafish10.1021/acs.analchem.3c02381 ↗
47. Autophagic lysosome reformation in health and disease10.1080/15548627.2022.2128019 ↗
48. Monitoring autophagy with Atg4B protease-activated aggregation-induced emission probe10.1002/adfm.202108571 ↗
49. One stone, three birds: pH triggered transformation of aminopyronine and iminopyronine based lysosome targeting viscosity probe for cancer visualization10.1021/acs.analchem.0c04644 ↗
50. A novel nanozyme to enhance radiotherapy effects by lactic acid scavenging, ROS generation, and hypoxia mitigation10.1002/advs.202403107 ↗
51. A multifunctional covalent organic framework nanozyme for promoting ferroptotic radiotherapy against esophageal cancer10.1021/acsnano.3c06967 ↗
52. Lysosomes as a therapeutic target10.1038/s41573-019-0036-1 ↗
53. Targeted nanomedicine in cisplatin-based cancer therapeutics10.1016/j.jconrel.2022.03.049 ↗
54. An engineered nanoplatform inhibiting energy metabolism and lysosomal activity of tumor cells to multiply cisplatin-based chemotherapy10.1016/j.biomaterials.2023.122354 ↗